The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Metabolic profiles as predictive biomarkers of erlotinib-induced adverse effects in patients with non-small cell lung cancer.
A. Hamada
No relevant relationships to disclose
J. Sasaki
No relevant relationships to disclose
S. Saeki
No relevant relationships to disclose
N. Iwamoto
No relevant relationships to disclose
M. Inaba
No relevant relationships to disclose
S. Ushijima
No relevant relationships to disclose
H. Kishi
No relevant relationships to disclose
S. Fujii
No relevant relationships to disclose
H. Semba
No relevant relationships to disclose
K. Kashiwabara
No relevant relationships to disclose
Y. Tsubata
No relevant relationships to disclose
Y. Kai
No relevant relationships to disclose
T. Isobe
No relevant relationships to disclose
H. Kohrogi
No relevant relationships to disclose
H. Saito
No relevant relationships to disclose